-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As national policies continue to focus on pharmaceutical innovation, the development of China's pharmaceutical innovation industry has also begun to accelerate
.
It is understood that in order to seize new market development opportunities, pharmaceutical companies are currently increasing investment in innovative drug research and development, and a large number of pharmaceutical companies have begun to gradually enter the harvest period
.
According to data, in 2021, China's National Medical Products Administration (NMPA) has approved 76 new drugs (excluding new indications and vaccines) for the market, and in 2022, less than a month later, A number of innovative drugs have been approved for clinical use and listed on the market
.
For example, Kelun Pharmaceutical recently announced that a new class 1 drug, KL340399 injection, was approved for clinical use.
This drug is a new generation of small molecule STING agonists, and no drug with the same target has been approved for marketing
.
In addition, in terms of innovative traditional Chinese medicine drugs, Yili Pharmaceutical's Huzhen Qingfeng Capsules and Yiling Pharmaceutical's Jieyu Chufan Capsules have also been approved one after another
.
In this regard, the industry believes that batches of self-developed first-class innovative drugs have continued to emerge, which fully reflects the vigorous development of China's domestic innovative drugs and the rising enthusiasm of enterprises for R&D
.
The industry expects that, driven by policies, combined with the help of the Science and Technology Innovation Board and the registration system, the capital of innovative drugs will continue to swarm, and domestic innovative drugs will accelerate into the harvest period.
Benefit more patients in the field of major diseases; at the same time, it will further reduce the dependence on foreign new drugs and accelerate import substitution
.
On the whole, the development of domestic innovative drugs is in full swing, and the development of innovative pharmaceutical companies is also constantly ushering in good news
.
In this context, what is the way out for generic drugs? In this regard, analysts believe that generic drugs will still be the focus of the development of the domestic pharmaceutical industry for a long time in the future, and there will still be a broad market
.
It is understood that in recent years, the state has successively issued a number of policies to encourage the development and innovation of the generic drug industry, such as the "Announcement on Matters Concerning the Quality and Efficacy Consistency Evaluation of Generic Drugs" and "Opinions on Deepening the Reform of the Medical Security System" , "Announcement on Carrying out the Quality and Efficacy Consistency Evaluation of Chemical Injection Generic Drugs" and other policies have provided a clear and broad market prospect for the development of the generic drug industry, and provided a good production and operation environment for enterprises
.
In addition, from the perspective of the pharmaceutical market structure, most of the pharmaceutical companies in China are still dominated by generic drugs
.
According to incomplete statistics, in the domestic pharmaceutical market in 2020, the proportion of generic drugs will be as high as 63%, and the market share of generic drugs is still increasing
.
However, although China's generic drug market is huge at present, there are actually some problems in its development
.
For example, the quality standards of generic drugs are relatively low; the product quality of pharmaceutical companies is relatively low and cannot meet market demand; the supply of cheap generic drugs has been in short supply for a long time; there are relatively few companies with R&D and production capacity in the generic drug industry
.
Therefore, in order to better promote the development of the generic drug industry and meet people's drug needs, China also needs to continuously improve industry policies, improve industry standards and drug quality and safety levels, and create a healthy and good environment and institutional guarantee for pharmaceutical companies; , enterprises also need to continuously improve the quality of generic drugs, support the research and development and use of high-end generic drugs, and promote the substitution of generic drugs
.
It is worth mentioning that industry analysts believe that improved new drugs may become a breakthrough in generic drug innovation in the future
.
It is reported that judging from the approval of new improved drugs in China, due to the long life cycle and high rate of return of improved new drugs, the development process of domestic improved new drugs has been accelerating in recent years.
Some domestic pharmaceutical companies include Luye Pharma, Xuantai Medicine, Orsay Kang and others are already actively deploying
.
.
It is understood that in order to seize new market development opportunities, pharmaceutical companies are currently increasing investment in innovative drug research and development, and a large number of pharmaceutical companies have begun to gradually enter the harvest period
.
According to data, in 2021, China's National Medical Products Administration (NMPA) has approved 76 new drugs (excluding new indications and vaccines) for the market, and in 2022, less than a month later, A number of innovative drugs have been approved for clinical use and listed on the market
.
For example, Kelun Pharmaceutical recently announced that a new class 1 drug, KL340399 injection, was approved for clinical use.
This drug is a new generation of small molecule STING agonists, and no drug with the same target has been approved for marketing
.
In addition, in terms of innovative traditional Chinese medicine drugs, Yili Pharmaceutical's Huzhen Qingfeng Capsules and Yiling Pharmaceutical's Jieyu Chufan Capsules have also been approved one after another
.
In this regard, the industry believes that batches of self-developed first-class innovative drugs have continued to emerge, which fully reflects the vigorous development of China's domestic innovative drugs and the rising enthusiasm of enterprises for R&D
.
The industry expects that, driven by policies, combined with the help of the Science and Technology Innovation Board and the registration system, the capital of innovative drugs will continue to swarm, and domestic innovative drugs will accelerate into the harvest period.
Benefit more patients in the field of major diseases; at the same time, it will further reduce the dependence on foreign new drugs and accelerate import substitution
.
On the whole, the development of domestic innovative drugs is in full swing, and the development of innovative pharmaceutical companies is also constantly ushering in good news
.
In this context, what is the way out for generic drugs? In this regard, analysts believe that generic drugs will still be the focus of the development of the domestic pharmaceutical industry for a long time in the future, and there will still be a broad market
.
It is understood that in recent years, the state has successively issued a number of policies to encourage the development and innovation of the generic drug industry, such as the "Announcement on Matters Concerning the Quality and Efficacy Consistency Evaluation of Generic Drugs" and "Opinions on Deepening the Reform of the Medical Security System" , "Announcement on Carrying out the Quality and Efficacy Consistency Evaluation of Chemical Injection Generic Drugs" and other policies have provided a clear and broad market prospect for the development of the generic drug industry, and provided a good production and operation environment for enterprises
.
In addition, from the perspective of the pharmaceutical market structure, most of the pharmaceutical companies in China are still dominated by generic drugs
.
According to incomplete statistics, in the domestic pharmaceutical market in 2020, the proportion of generic drugs will be as high as 63%, and the market share of generic drugs is still increasing
.
However, although China's generic drug market is huge at present, there are actually some problems in its development
.
For example, the quality standards of generic drugs are relatively low; the product quality of pharmaceutical companies is relatively low and cannot meet market demand; the supply of cheap generic drugs has been in short supply for a long time; there are relatively few companies with R&D and production capacity in the generic drug industry
.
Therefore, in order to better promote the development of the generic drug industry and meet people's drug needs, China also needs to continuously improve industry policies, improve industry standards and drug quality and safety levels, and create a healthy and good environment and institutional guarantee for pharmaceutical companies; , enterprises also need to continuously improve the quality of generic drugs, support the research and development and use of high-end generic drugs, and promote the substitution of generic drugs
.
It is worth mentioning that industry analysts believe that improved new drugs may become a breakthrough in generic drug innovation in the future
.
It is reported that judging from the approval of new improved drugs in China, due to the long life cycle and high rate of return of improved new drugs, the development process of domestic improved new drugs has been accelerating in recent years.
Some domestic pharmaceutical companies include Luye Pharma, Xuantai Medicine, Orsay Kang and others are already actively deploying
.
